Hyperglycemia on admission, an excess risk for infarction

Reference: Planer et al. International Journal of Cardiology 2012 (in press)

Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with patients without DM. Epidemiological studies found increased micro and macro vascular complications with blood glucose levels lower than those defined for the diagnosis of DM (“IGT”). New studies show that patients without DM but admitted with diagnosis of STEMI hyperglycemic, 40% were glucose intolerant and only 25% were undiagnosed DM.

Hyperglycemia on admission is associated with increased morbidity and mortality in the short follow-up, as well as with the follow-up of patients without DM. However, most of its predictive information comes from large studies of thrombolytic era, although data available from patients.

A recent sub-analysis (n = 3400 patients, 566 DM) of HORIZON-AMI randomized study evaluated the prognostic power of fasting glucose prior to primary angioplasty in patients with STEMI. Authors stratified patients according tertiles fasting glucose level. The median blood glucose of the total population was 138.0 mg / dl [interquartile 115.4, 171.0]. 30 day adjusted mortality was higher in the upper tertile blood glucose (relative risk [95% confidence interval] = 3.53 [1.89, 6.60], p <0.0001), both in DM patients (4.40 [2.04, 9.50], p = 0.0002) and non-DM patients (3.33 [1.16, 9.55], p = 0.03). The cut-off value for predicting blood glucose 30 day mortality was 169 mg / dl (ROC curve = 0.69), 149 mg / dl for non-DM (ROC curve = 0.77) and 231 mg / dl for DM (AUC = 0.69). In addition, basal hyperglycemia was an independent predictor of mortality at 3 years (1.93 [1.35, 2.76], P = 0.0003), in DM (2.65 [1.28, 5.47], P = 0.008) and in non-DM (1.58 [1.05, 2.36], P = 0.03).

Conclusion: In patients with STEMI referred for primary angioplasty, the presence of hyperglycemia on admission is an independent predictor of mortality in the short and long term in patients with or without DM.

Comment: This retrospective study is the first to provide cut-off values

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Gentileza del Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently associated with severe mitral regurgitation (MR), either...